论文部分内容阅读
目的观察缬沙坦对高血压合并持续性心房颤动(房颤)患者在降压同时对其心率(HR)、血压(BP)、左心房结构及左心室功能的影响。方法对2004年1月至2005年6月哈尔滨医科大学第一临床医学院收治的高血压合并持续性房颤患者106例,在控制心室率、预防血栓治疗的基础上应用缬沙坦80mg/d,对照组用依那普利10mg/d。3个月、6个月后对照观察其对心率、血压、左心房结构及左心室功能的影响。缬沙坦组54例,依那普利组52例。结果分别观察3个月、6个月后两组血压、心率均控制理想,两组间差异无显著性意义(P>0.05)。左心房直径缬沙坦组治疗前平均(50±7)mm,3个月后为(46±4)mm,6个月后为(40±3)mm,与治疗前相比差异有显著性意义。依那普利组3个月、6个月后左心房也有缩小,但差异不显著。治疗组治疗前NY分级Ⅱ、Ⅲ级占64%,治疗后3个月、6个月分别下降至33%、15%。而依那普利组也有明显下降,3个月、6个月分别下降至45%、25%,下降程度不如缬沙坦组明显。结论长期应用缬沙坦(3个月以上)可以显著改善左心房结构、左心室功能和持续性房颤患者的长期预后。
Objective To observe the effects of valsartan on heart rate (HR), blood pressure (BP), left atrial structure and left ventricular function in hypertensive patients with persistent atrial fibrillation (AF). Methods From January 2004 to June 2005, 106 patients with hypertension and persistent atrial fibrillation admitted to the First Clinical Medical College of Harbin Medical University were enrolled in this study. Valsartan 80 mg / d , The control group with enalapril 10mg / d. 3 months, 6 months after the control of their heart rate, blood pressure, left atrial structure and left ventricular function. Valsartan group 54 cases, enalapril group 52 cases. The results were observed 3 months, 6 months after the two groups were ideal control of blood pressure, heart rate, no significant difference between the two groups (P> 0.05). The average diameter of the left atrium before valsartan treatment was (50 ± 7) mm, (46 ± 4) mm after 3 months and (40 ± 3) mm after 6 months, which was significantly different from that before treatment significance. Enalapril group 3 months, 6 months after the left atrium has shrunk, but the difference was not significant. The treatment group before treatment NY grade Ⅱ, Ⅲ grade accounted for 64%, 3 months after treatment, 6 months decreased to 33%, 15%. The enalapril group also significantly decreased, 3 months, 6 months decreased to 45%, 25%, the decline is not as obvious as valsartan group. Conclusion Long-term valsartan (> 3 months) can significantly improve the long-term prognosis of patients with left atrial structure, left ventricular function, and persistent atrial fibrillation.